Table 2 Targets and potential treatments according to the specific endotypes and phenotypes
From: Endotype-driven treatment in chronic upper airway diseases
Endotypes-targets | Allergic rhinitis | Idiopathic rhinitis | Infectious rhinitis | CRSwNP | CRSsNP |
|---|---|---|---|---|---|
Type 2 inflammation | |||||
IgE | Omalizumab (sc/iv) | Â | Â | Omalizumab (sc) | Â |
Legelizumab | Â | Â | Legelizumab | Â | |
Ml prime mIgE | Quilizumab | Â | Â | Quilizumab | Â |
IL-5 | Mepolizumab | Â | Â | Mepolizumab (iv) | Â |
Reslizumab | Â | Â | Reslizumab (sc) | Â | |
IL-5Ra | Benralizumab | Â | Â | Benralizumab | Â |
IL-4/13 | Dupilumab | Â | Â | Dupilumab (sc) | Â |
CRTH2 | OC000459 (po) | Â | Â | OC000459 | Â |
BI 671800 (po) | Â | Â | BI671800 | Â | |
GATA-3 | GATA-3 spec.DNAzyme | Â | Â | GATA-3 spec.DNAzyme | Â |
Siglec-8 | AK001 | Â | Â | Â | Â |
Non-type 2 inflammation | |||||
Neutrophilic inflammation | Â | Â | Â | Â | Â |
Th1 | Â | Â | Â | Â | Â |
Th17/Th22 | Â | Â | Brodalumab | Â | Brodalumab |
Neurogenic endotype | |||||
TRPV1 | Â | Capsaicin (in) SB-705498 (IN) | Â | Â | Â |
Barrier dysfunction | |||||
None | Â | Â | Â | Â | Â |